Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on May 19, 2020, covering events occurring on May 14, 2020, and May 19, 2020. The company is a Delaware corporation headquartered in San Diego, CA, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics and Capital Events
The filing details two unregistered private placements of common stock to the Company's directors and CEO:
- May 14, 2020 Transaction: Sale of 146,854 shares at $1.43 per share, generating gross proceeds of $210,000.
- May 19, 2020 Transaction: Sale of 594,615 shares, generating gross proceeds of $810,000 (price per share not explicitly stated in the text).
- Total Gross Proceeds: $1,020,000 from these two specific transactions.
The filing does not provide data on revenue, profit, operating cash flow, margins, debt levels, or general liquidity metrics beyond the proceeds from these equity sales.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of capital through the sale of unregistered securities to insiders. The securities were issued pursuant to exemptions under Section 4(a)(2) and Rule 506 of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the securities purchase agreements. The filing references a press release (Exhibit 99.1) for further details on the May 19 transaction. No specific forward-looking guidance, risk factors, or contingencies are detailed within the text of this specific 8-K filing.
Key Facts for Investor Verification
- Verify the exact price per share for the May 19, 2020 transaction, as the text only provides total proceeds ($810,000) and share count (594,615).
- Confirm the total number of shares outstanding post-transaction to assess dilution impact.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for any specific covenants or restrictions associated with the insider investment.
- Check the referenced press release (Exhibit 99.1) for the stated use of proceeds and strategic rationale.